Pol O, Ferrer I, Puig M M
Department of Anesthesiology, Hospital Universitario del Mar, Barcelona, Spain.
J Pharmacol Exp Ther. 1994 Jul;270(1):386-91.
The aim of the study was to determine the effects of intestinal inflammation induced by croton oil on the antitransit action of systemically administered receptor-specific opioids. Our hypothesis was that inflammation would "sensitize" opioid receptors in peripheral and/or central terminals of myenteric and submucous plexus neurons and enhance the effects of exogenously administered opioids. Diarrhea was induced by p.o. administration of croton oil and was demonstrated by weight loss and increased gastrointestinal transit. Histologically, an increased number of clear vesicles in the cytoplasm of jejunal epithelial cells and enlarged spaces filled with fine granular material in the extravascular compartment were observed. Subcutaneous morphine and fentanyl produced dose-related inhibitions of gastrointestinal transit in saline-treated controls with ED50 values of 1.24 +/- 0.06 and 0.036 +/- 0.010 mg/kg, respectively. In animals with diarrhea, dose-response curves were parallel and shifted to the left with a significant decrease in ED50 values of 2.95 times for morphine and 1.89 for fentanyl. The effects of the delta agonist Tyr-D-Pen-Gly-Phe-D-Pen, but those of U50,488H [trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolydynil)cyclohexyl) benzeneazetamine] also were increased significantly during diarrhea associated with inflammation. Naloxone (0.1 mg/kg), MR-2266 [(-)-a-5,9-diethyl-2'-hydroxy-2-(3-furylmethyl)-6,7-benzomorphan] (3 mg/kg) and naltrindole (1 mg/kg) antagonized the effects of the receptor-specific opioid agonists used in the study. Our results show that the potency of s.c. mu and delta opioids is increased during inflammation of the gut and that the effect is mediated by the same type of opioid receptors present in the noninflamed tissue. These results support the view that a sensitization of opioid receptors occurs during acute inflammation of the gut.
本研究的目的是确定巴豆油诱导的肠道炎症对全身给药的受体特异性阿片类药物抗转运作用的影响。我们的假设是,炎症会使肌间神经丛和黏膜下神经丛神经元的外周和/或中枢终末中的阿片受体“敏感化”,并增强外源性阿片类药物的作用。通过口服巴豆油诱导腹泻,通过体重减轻和胃肠道转运增加来证明。组织学上,观察到空肠上皮细胞胞质中清亮小泡数量增加,血管外间隙中充满细颗粒物质的间隙扩大。皮下注射吗啡和芬太尼在生理盐水处理的对照组中产生与剂量相关的胃肠道转运抑制,ED50值分别为1.24±0.06和0.036±0.010mg/kg。在腹泻动物中,剂量反应曲线平行且向左移动,吗啡的ED50值显著降低2.95倍,芬太尼降低1.89倍。δ激动剂Tyr-D-Pen-Gly-Phe-D-Pen的作用,但U50,488H[反式-3,4-二氯-N-甲基-N-(2-(1-吡咯烷基)环己基)苯乙胺]的作用在与炎症相关的腹泻期间也显著增加。纳洛酮(0.1mg/kg)、MR-2266[(-)-α-5,9-二乙基-2'-羟基-2-(3-呋喃基甲基)-6,7-苯并吗啡烷](3mg/kg)和纳曲吲哚(1mg/kg)拮抗了本研究中使用的受体特异性阿片类激动剂的作用。我们的结果表明,在肠道炎症期间,皮下注射μ和δ阿片类药物的效力增加,并且这种作用是由非炎症组织中存在的相同类型的阿片受体介导的。这些结果支持了在肠道急性炎症期间阿片受体发生敏感化这一观点。